Sodium Sulfacetamide 9% - Sulfur 4%

Manufacturer
Akron Pharma Inc.
Effective date
2024-09-24
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
full-release
Hydrated at
2026-05-31 21:12:56

Label at a glance#

ProductSodium Sulfacetamide 9% - Sulfur 4%
Active ingredientSULFACETAMIDE SODIUM, SULFUR
Label structure12 sections

Dosage and administration

Apply Sodium Sulfacetamide 9% - Sulfur 4% Topical Suspension once or twice daily to affected areas, or as directed by your physician. Wet skin and liberally apply to areas to be cleansed. Massage gently into skin for 10-20 seconds, working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing off Sodium Sulfacetamide 9% - Sulfur 4% Topical Suspension sooner or using le...

Storage and handling

Store at controlled room temperature, 15° - 30°C (59° - 86°F). Protect from freezing. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. All prescription substitutions using this product shall be made subject to state and federal statutes as applicable.  NOTE: this is not an Orange Book product and has not been subjected to FDA therapeutic equivalency or other equivalency testing. No representation is mad...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx Only

DESCRIPTION

SPL UNCLASSIFIED SECTION

Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Chemically sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. The structural formula is:

Each mL of Sodium Sulfacetamide 9% - Sulfur 4% Topical Suspension contains 90 mg of Sodium Sulfacetamide and 40 mg of Sulfur in a formulation containing aloe vera gel, butylated hydroxytoluene, cetyl alcohol, edetate disodium, glyceryl monostearate, green tea extract, magnesium aluminum silicate, methylparaben, PEG- 40 stearate, PEG-60 almond glyceride, PEG-6 caprylic/capric glyceride, polyethylene glycol, propylparaben, purified water, sodium lauryl sulfate, sodium thiosulfate, stearyl alcohol, xanthan gum

structstruct

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours. The exact mode of action of sulfur in the treatment of acne is not known, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.

INDICATIONS

INDICATIONS & USAGE SECTION

Sodium Sulfacetamide 9% - Sulfur 4% Topical Suspension is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

Sodium Sulfacetamide 9% - Sulfur 4% Topical Suspension is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. Sodium Sulfacetamide 9% - Sulfur 4% Topical Suspension is not to be used by patients with kidney disease.

WARNINGS

WARNINGS SECTION

Although rare, sensitivity to sodium sulfacetaminde may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.

FOR EXTERNAL USE ONLY. Keep away from eyes. Keep out of reach of children. Keep container tightly closed.

PRECAUTIONS

PRECAUTIONS SECTION

General - If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

Information for patients

Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. If excessive irritation develops, discontinue use and consult your physician.

Carcinogenesis, Mutagenesis and Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

PREGNANCY:

Category C. Animal reproduction studies have not been conducted with Sodium Sulfacetamide 9% - Sulfur 4% Topical Suspension. It is not known whether Sodium Sulfacetamide 9% - Sulfur 4% Topical Suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Sulfacetamide 9% - Sulfur 4% Topical Suspension should be given to a pregnant woman only if clearly needed.

NURSING MOTHERS:

It is not known whether sodium sulfacetamide is excreted in the human milk following topical use of Sodium Sulfacetamide 9% - Sulfur 4% Topical Suspension. However, small amounts of orally administered sulfonamides have been reported to be eliminated in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when Sodium Sulfacetamide 9% - Sulfur 4% Topical Suspension is administered to a nursing woman.

PEDIATRIC USE:

Safety and effectiveness in children under the age of 12 have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Although rare, sodium sulfacetamide may cause local irritation.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Apply Sodium Sulfacetamide 9% - Sulfur 4% Topical Suspension once or twice daily to affected areas, or as directed by your physician. Wet skin and liberally apply to areas to be cleansed. Massage gently into skin for 10-20 seconds, working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing off Sodium Sulfacetamide 9% - Sulfur 4% Topical Suspension sooner or using less often.

HOW SUPPLIED

HOW SUPPLIED SECTION

Sodium Sulfacetamide 9% - Sulfur 4% Topical Suspension is available in 16 fl oz (473 mL) bottles, NDC 71399-0482-6.

STORAGE AND HANDLING SECTION

Store at controlled room temperature, 15° - 30°C (59° - 86°F). Protect from freezing.

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

All prescription substitutions using this product shall be made subject to state and federal statutes as applicable. NOTE: this is not an Orange Book product and has not been subjected to FDA therapeutic equivalency or other equivalency testing. No representation is made as to generic status or bioequivalency. Each person recommending a prescription substitution using this product shall make such recommendations based on each such person’s professional opinion and knowledge, upon evaluating the active ingredients, excipients, inactive ingredients and chemical formulation information provided herein.

QUESTIONS?

Please Call 1(877) 225-6999

Manufactured for:
Akron Pharma, Inc.
Fairfield, NJ 07004
Manufactured in U.S.A

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

image descriptionimage description

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1001714sulfacetamide sodium 9 % / sulfur 4 % Medicated Liquid SoapPSN4
1001714sulfacetamide sodium 90 MG/ML / sulfur 40 MG/ML Medicated Liquid SoapSCD4
1001714sulfacetamide sodium 9 % / sulfur 4 % Medicated Liquid SoapSY4

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
SULFACETAMIDE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
4073022c-5d5d-48f5-82ed-091ad146a4b2Product name120171211
9ffbd0ae-0bce-c086-b707-f0da5f8cd7c5Product name120150828
0304b7d2-7a07-d53b-750f-36012ae6612eProduct name120140508
64c0cc7e-6478-3ca1-8cd7-9a1251d5a3f6Product name120140508
9ae74339-0a3d-82e9-5dd1-88bd2607bd6bProduct name120140508
e44e38a9-2d9e-b0e2-cce9-490554639f3dProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
71399-0482-6Sodium Sulfacetamide 9% - Sulfur 4%473 mL in 1 BOTTLE, PLASTICSUSPENSION4734

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
71399-0482SODIUM SULFACETAMIDE 9% - SULFUR 4% (SULFACETAMIDE SODIUM, SULFUR) SUSPENSION [AKRON PHARMA INC.]4Current NDC, Legacy NDC, 1 package rows20240926_173fd4d6-1efb-46e3-bf8e-565a265b6d6e.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
71399-0482-6ML - Milliliter71399-0482cff9345a-56aa-4f49-a46c-d805cfd1a87512021-01-08

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 23 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
71399-048271399-0482-6

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 20 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Sodium Sulfacetamide 9% - Sulfur 4%SULFACETAMIDE SODIUM, SULFURAkron Pharma Inc.173fd4d6-1efb-46e3-bf8e-565a265b6d6e2024-09-24Warnings, Adverse reactionsExact identifier
ndc (package): 71399-0482-6
ndc (product): 71399-0482
ndc11 (package): 71399048206
spl id: 869f17c5-f005-4d57-b97e-f98584ee34b9
spl set id: 173fd4d6-1efb-46e3-bf8e-565a265b6d6e

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.